Detailansicht

Wissensnetz

Person

Maria Gavriatopoulou

Ärztin

Name	Maria Gavriatopoulou
Ort	Griechenland
Geschlecht	weiblich
Akademischer Grad bzw. Titel	PhD
Beruf	Ärztin (charakteristischer Beruf)
Beziehung	Ethnikon kai Kapodistriakon Panepistēmion
Datensatztyp	Person
GND-Nummer	1191791572
Datensatz-ID	1191791572
Beteiligt an alle anzeigen Efficacy and immune modulation associated with the addition of IMiDs to Daratumumab backbone in multiple myeloma patients refractory to both drug classes: resetting synergistic activity Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine COVID-19: time to flatten the infodemic curve Carfilzomib-associated renal toxicity is common and unpredictable: a comprehensive analysis of 114 multiple myeloma patients Emerging treatment strategies for COVID-19 infection Organ-specific manifestations of COVID-19 infection Long PFS of more than 7 years is achieved in 9% of myeloma patients in the era of conventional chemotherapy and of first-generation novel anti-myeloma agents: a single-center experience over 20-year period Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias

Hinweis

Die Betaversion beinhaltet noch nicht alle Funktionen und Informationen des Katalogs des DNB-Portals. Falls Sie Informationen vermissen oder ein Medium bestellen wollen, besuchen Sie bitte die entsprechende Seite im Katalog des DNB-Portals über folgenden Link:

Katalog der Deutschen Nationalbibliothek

Maria Gavriatopoulou

Efficacy and immune modulation associated with the addition of IMiDs to Daratumumab backbone in multiple myeloma patients refractory to both drug classes: resetting synergistic activity

Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine

COVID-19: time to flatten the infodemic curve

Carfilzomib-associated renal toxicity is common and unpredictable: a comprehensive analysis of 114 multiple myeloma patients

Emerging treatment strategies for COVID-19 infection

Organ-specific manifestations of COVID-19 infection

Long PFS of more than 7 years is achieved in 9% of myeloma patients in the era of conventional chemotherapy and of first-generation novel anti-myeloma agents: a single-center experience over 20-year period

Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma

European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias